NASDAQ:KIN

Kindred Biosciences Stock Forecast, Price & News

$4.86

-0.07 (-1.42 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.65

Now: $4.86▼

$5.05

50-Day Range

$3.71

MA: $4.49▼

$5.15

52-Week Range

$3.11

Now: $4.86▼

$11.93

Volume224,496 shs

Average Volume333,293 shs

Market Capitalization$191.93 million

P/E RatioN/A

Dividend YieldN/A

Beta1.19

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.

MarketRank^™

Overall MarketRank^™

1.54 out of 5 stars

Medical Sector

378th out of 1,922 stocks

Pharmaceutical Preparations Industry

197th out of 771 stocks

3.4 Analyst's Opinion

Consensus Rating
Kindred Biosciences has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.56, Kindred Biosciences has a forecasted upside of 117.3% from its current price of $4.86.
Amount of Analyst Coverage
Kindred Biosciences has only been the subject of 1 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Kindred Biosciences has received 364 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Kindred Biosciences has received 346 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Kindred Biosciences has received 51.27% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote “Outperform” if you believe KIN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Kindred Biosciences does not currently pay a dividend.
Dividend Growth
Kindred Biosciences does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kindred Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $260,460.00 in company stock.
Percentage Held by Insiders
Only 12.63% of the stock of Kindred Biosciences is held by insiders.
Percentage Held by Institutions
66.31% of the stock of Kindred Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Kindred Biosciences are expected to decrease in the coming year, from ($0.50) to ($0.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kindred Biosciences is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kindred Biosciences is -7.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kindred Biosciences has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KIN

Previous Symbol

CUSIPN/A

CIK1561743

Webkindredbio.com

Phone650-701-7901

Employees156

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.26

Current Ratio12.71

Quick Ratio12.64

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.26 million

Price / Sales45.05

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.10 per share

Price / Book2.31

Profitability

EPS (Most Recent Fiscal Year)($1.59)

Net Income$-61,390,000.00

Net Margins-62.50%

Return on Equity-25.42%

Return on Assets-18.20%

Miscellaneous

Outstanding Shares39,492,000

Market Cap$191.93 million

Next Earnings Date3/15/2021 (Estimated)

OptionableOptionable

$4.86

-0.07 (-1.42 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

How has Kindred Biosciences' stock price been impacted by COVID-19?

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KIN stock has decreased by 39.9% and is now trading at $4.86.
View which stocks have been most impacted by COVID-19.

Is Kindred Biosciences a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kindred Biosciences stock.
View analyst ratings for Kindred Biosciences or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Kindred Biosciences?

Wall Street analysts have given Kindred Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kindred Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Kindred Biosciences.

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) announced its quarterly earnings results on Monday, November, 9th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.31). The biopharmaceutical company earned $1.04 million during the quarter, compared to the consensus estimate of $0.57 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 25.42% and a negative net margin of 62.50%.
View Kindred Biosciences' earnings history.

What price target have analysts set for KIN?

6 equities research analysts have issued twelve-month target prices for Kindred Biosciences' stock. Their forecasts range from $9.00 to $13.00. On average, they expect Kindred Biosciences' share price to reach $10.56 in the next twelve months. This suggests a possible upside of 117.3% from the stock's current price.
View analysts' price targets for Kindred Biosciences or view Wall Street analyst' top-rated stocks.

Who are some of Kindred Biosciences' key competitors?

Some companies that are related to Kindred Biosciences include Aclaris Therapeutics (ACRS), Dynavax Technologies (DVAX), Clovis Oncology (CLVS), Albireo Pharma (ALBO), Ardelyx (ARDX), Syros Pharmaceuticals (SYRS), AnaptysBio (ANAB), Chinook Therapeutics (KDNY), Emisphere Technologies (EMIS), Graybug Vision (GRAY), Inventiva (IVA), Basilea Pharmaceutica (BPMUF), Eagle Pharmaceuticals (EGRX), Rigel Pharmaceuticals (RIGL) and Homology Medicines (FIXX).
View all of KIN's competitors.

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the following people:

Dr. Richard Chin, Co-Founder, Pres, CEO & Director (Age 53, Pay $899k)
Ms. Denise M. Bevers, Co-Founder & Director (Age 53, Pay $633.13k)
Ms. Wendy K. Wee, CFO & Sec. (Age 67, Pay $438.15k)
Dr. Hangjun Zhan, Chief Scientific Officer (Age 60, Pay $432.98k)
Ms. Katja Buhrer, Chief of Staff, VP of Corp. Devel. & Investor Relations

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $4.86.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $191.93 million and generates $4.26 million in revenue each year. The biopharmaceutical company earns $-61,390,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Kindred Biosciences employs 156 workers across the globe.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is kindredbio.com.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here